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Abstract 
 
Introduction - Survivors of congenital diaphragmatic hernia have increased with the 
introduction of new treatment modalities and have been reported to experience ongoing 
medical morbidity until adulthood. 
Aim - To describe the long-term functional impact of congenital diaphragmatic hernia 
repair on the survivors of a single institution cohort of newborns, over a 14-year period. 
Methods – The follow up medical charts of 39 congenital diaphragmatic hernia 
survivors treated at a tertiary neonatal intensive care unit, from January 1997 to 
December 2010, were analyzed. 
Results - The median age at follow up was 70 (4 – 162) months. Gastrointestinal 
sequelae were the most common with 12 (30.7%) patients affected by failure to thrive. 
Chronic lung disease occurred in 5 (12.8%) patients, neurodevelopmental delay in 5 
(12.8%), musculoskeletal sequelae in 6 (15.3%), recurrence of hernia in 4 (10.2%) and 2 
(7.6%) were deceased. 
Conclusion – Congenital diaphragmatic hernia survivors are a group of patients that 
requires long term periodic follow up in a multidisciplinary setting to provide adequate 
support and improve their quality of life. 
 
 
 
  Key words: congenital diaphragmatic hernia; survivors; follow-up; gastrointestinal; 
neurodevelopmental; musculoskeletal. 
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INTRODUCTION 
 
Survivors of congenital diaphragmatic hernia (CDH) have increased with the 
introduction of new treatment modalities, including gentle ventilation with permissive 
hypercapnea, high frequency ventilation, inhaled nitric oxide, and extracorporeal 
membrane oxygenation (ECMO) [1-3].  
CDH survivors have been reported to experience ongoing medical morbidity [4]. Some 
institution reports of long-term sequelae include pulmonary and gastrointestinal 
problems, neurodevelopmental morbidity, orthopaedic disorders, and a less favourable 
quality of life [4]. Although some single-institution reports have addressed the issue of 
long-term outcome of CDH survivors, the variability in patient populations, 
management, and methods for and length of follow-up make if difficult to draw firm 
conclusions about the quality of life of these patients.  
The aim of this review is to describe the long-term functional impact of CDH repair on 
the survivors of a single institution cohort of newborns over a 14-year period.   
 
 
METHODS 
 
The follow up medical charts of 39 CDH survivors treated at a tertiary neonatal 
intensive care unit (NICU), from January 1997 to December 2010, were analyzed. Data 
retrieved included actual age, weight, length/ height, head circumference, respiratory, 
cardiovascular, neurological, gastrointestinal and musculoskeletal outcomes. Whenever 
data seemed incomplete or any doubt arouse in the medical charts analysis the child`s 
current clinical problems, if any, were assessed on a telephone-based parent medical 
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history, which addressed nutritional status, cardiopulmonary and gastrointestinal 
problems, as well as issues with vision, hearing, speech, behaviour, learning, muscle 
tone and orthopaedic problems. 
After discharge from hospital, CDH survivors are cared for in a multidisciplinary follow 
up. Follow up schedule may change as indicated, but usually includes regular 
evaluations every three months during the first year of life, every six months during the 
second year of life, and once a year after two years of age. Anthropometrical indexes 
are evaluated in all visits and nutritional support by a dietician is indicated when weight 
is below the fifth percentile, or children have crossed down two major growth 
percentiles without any other evident aetiology, according to the charts of the National 
Center for Health Statistics, the growth reference data used in Portugal. Patients that 
present clinically relevant respiratory problems are accompanied by a paediatric 
pulmonologist. Since 2006, the respitatory syncitial virus infection immunoprophylaxis 
with Palivizumab is performed to all CDH survivors. The follow up and treatment of 
gastro-esophageal reflux disease is performed at the consultation of paediatric surgery. 
Cardiovascular evaluation and follow up is indicated when the examination is abnormal 
at discharge from the NICU, or when signs or symptoms of persistent pulmonary 
hypertension are present, as well as in patients on supplemental oxygen. 
Neurodevelopmental follow up is performed by a specialized team in symptomatic or 
patients with previous abnormalities. Brain imaging (ultrasound scan, computed 
tomography or magnetic resonance) is performed when there are previous anomalies or 
abnormal neurological signs. All patients are screened for audiological and visual 
deficits. Orthopaedic evaluation and physiotherapy are performed if indicated.  
We considered failure to thrive those children below the fifth percentile for age and 
those that have crossed down two major growth percentiles without any other evident 
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morbidity. Diagnosis of gastro-esophageal reflux was done using upper gastrointestinal 
contrast study. Patients with gastro-esophageal reflux disease were evaluated for 
esophagitis by endoscopic examination. We considered asthma in those patients 
presenting with more than three episodes of bronchospasm per year requiring 
bronchodilator treatment, when excluded other causes of bronchospasm such as allergic 
rhinitis, sinusitis, laringotracheobronchomalacia or stenosis, chronic exposure to 
environmental tobacco smoke, viral infections, gastro-esophageal reflux and cystic 
fibrosis [5]. Chronic lung disease was defined as oxygen requirement for at least six 
weeks for a transcutaneous saturation of 90% to 95%, along with the use of 
bronchodilators and inhaled steroids, or the need of respiratory support, and an 
abnormal chest radiograph. Neurodevelopment is assessed at the neurodevelopmental 
consultation using the Griffiths Mental Developmental Scale. Cerebral palsy is 
classified according to the Gross Motor Function Classification System [6]. 
 
 
RESULTS 
 
From a total of 80 newborns with CDH treated at our institution during the 
considered period, there were 39 (48.7%) survivors, 25 (64%) males and 14 (36%) 
females. They have presented in the neonatal period a median birth weight of 2810 
grams (1335-3725) and a median gestational age of 38 weeks (32-41). Eight (20.5%) 
were preterm and 20 (51%) had antenatal diagnosis of CDH. None presented any 
chromosomal or other congenital anomaly. Thirty five patients (90%) had a left 
side hernia and four patients (10%) had a right side hernia. The median neonatal 
intensive care unit stay was 21 days (7-167). 
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Follow-up since 1997 ranged between 1 and 14 years. The median age at follow up was 
70 (4 – 162) months. Survivors were not without morbidity. The sequelae found in the 
follow up are listed in table 1. Seven patients (17.9%) present one sequelae, six patients 
(15.3%) present two sequelae, three patients (7.6%) present three sequelae, two patients 
(5.1%) present four sequelae, and three patient (7.5%) presents six, seven and eight 
sequelae, respectively. In the remaining 10 patients no sequelae were detected.  No 
cases of sensorioneural hearing loss were diagnosed. One patient was deceased by three 
months old with respiratory failure associated to pneumonia and sepsis.  Another patient 
was deceased by eight months of age, after hernia recurrence repair, need for 
fundoplication, gastrostomy feeding, chronic lung disease, persistent pulmonary 
hypertension and multiple respiratory infections. 
The ongoing morbidity is more prevalent in those patients under five years of age, 
when compared to those over five, and this effect is more relevant on respiratory 
and gastrointestinal morbidity. 
The different aspects of therapy used in our CDH survivors are summarized in table 2. 
 
 
 
DISCUSSION 
 
More attention is now focused on long-term follow up of CDH survivors. The different 
centres treating CDH survivors have different follow up schedules and methods of 
therapy. They also have different protocols for the acute phase treatment at the NICU, 
and some provide ECMO support. Thus, comparing results of CDH survivors follow up 
from different centres make it difficult to draw firm conclusions [7,8]. With this idea in 
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mind we decided to present our own follow up schedule and the different aspects of the 
used therapy, and allow the readers to compare with their own centre experience. Of 
course, the proposed follow up schedule and therapies may change for patients requiring 
strict follow up with closer evaluations, or patents with particular specificities. In 
addition to long-term pulmonary sequelae in some survivors, follow up studies of 
infants with CDH have revealed associated non-pulmonary morbidity, including 
neurocognitive delay, gastroesophageal reflux and other gastrointestinal abnormalities, 
hearing loss, hernia recurrence, poor growth, and musculoskeletal abnormalities. 
 
Pulmonary outcome 
Obstructive symptoms such as bronchospasm or wheezing are frequently reported in 
CDH survivors, and a high proportion had been diagnosed with asthma  [9, 10 - 12].  In 
our study, obstructive symptoms were the most common respiratory morbidities. These 
symptoms are perceived to decline with ageing, although abnormalities in pulmonary 
function tests persist. Most adolescent CDH survivors are healthy and enjoy normal 
lives. However, in a significant proportion of patients, long-term pulmonary sequelae 
are detectable and dependent on the severity of lung hypoplasia and the degree of lung 
injury [9, 10].   
CDH survivors suffer from recurrent respiratory tract infections in infancy and early 
childhood [6, 12].   Recurrent pneumonia or a past history of pneumonia has been found 
in 26% to 39% of CDH survivors [6].       
Chronic lung disease (defined as the need for bronchodilators, diuretics, or oxygen 
supplementation) has been reported in CDH survivors, but its incidence is unclear [13]. 
One study reported chronic lung disease in 41% of the survivors [14].  Our experience 
is limited to five patients. The higher prevalence of chronic lung disease has been 
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reported in patients requiring ECMO or patch repair of the diaphragmatic defect. The 
severity of chronic lung disease may require prolonged respiratory support and 
tracheostomy. 
Recurrent herniation usually presents before three years of age.  In our study this 
occurred in four patients, by fourth and fifth month age. 
Although most CDH survivors are clinically normal, many of them present subclinical 
abnormalities in their chest radiographs, lung scintigraphy, and/or pulmonary functions 
tests. A careful respiratory follow up into adulthood is warranted. 
 
Neurological outcome 
A variable, but significant proportion of CDH survivors have neurological sequelae. In 
our sample, neurological sequelae were detected in seven (17.9%) of the survivors.  
Several factors are associated with neurodevelopmental outcome in CDH survivors 
[15]. The need for extracorporeal membrane oxygenation seems related to a poorer 
neurological outcome. Whether this reflects a more severe primary disease or is a 
consequence of a more aggressive treatment is unclear, and probably both are true.  A 
prolonged neonatal hospitalization, presumably reflecting the severity of the primary 
disorder, has been associated with a poorer neurological outcome [16].  A low socio-
economic status is another factor to enter in consideration with [9]. 
Neurodevelopmental outcome is likely to improve with ageing. It is not surprising that 
initial development may be delayed, but tend to improve with time and with resolution 
of other organ disorders. 
CDH survivors are at high risk of developing sensorioneural hearing loss, due to both 
the severity of primary disease and the exposure to numerous risk factors, including 
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ototoxic medications, and prolonged mechanical ventilation with high oxygen tensions.  
Fortunately none of our CDH survival presents sensorioneural hearing loss. 
Neuroimaging abnormalities are relatively frequent in CDH survivors, although their 
meaning is unclear [5].  In this study, one case of cerebral palsy with cortical atrophy 
was diagnosed. 
Long-term neurological follow up is warranted to early detection of neurological 
deficits and to provide adequate support. 
 
Gastrointestinal outcome 
Gastroesophageal reflux is the most common gastrointestinal sequelae [17]. The 
incidence of gastroesophageal reflux in CDH survivors is variable between institutions, 
presumably in relation to the diagnostic method used: pH monitoring, upper 
gastrointestinal contrast study, or clinical history. Despite its frequency, the 
pathophysiology of gastroesophageal reflux remains unclear, and many anatomical 
factors may contribute [18]. Surgical treatment may be indicated in selected patients.  
A significant number of CDH survivors show evidence of failure to thrive [2,17]. In our 
study, this was present in 15.3% (n=6) of the patients. Gastroesophageal reflux disease 
may be one of the etiologies, but many other factors are implicated in the pathogenesis 
of growth failure in CDH patients, such as chronic lung disease and oral aversion. 
Placement of a gastrostomy tube may be required in some patients with growth failure 
despite aggressive nutritional support.  
Other gastrointestinal surgical problems resulting in significant chronic morbidity 
include intestinal adhesions with obstruction, volvulus secondary to malrotation, 
intestinal perforation, and ischemia. None of these problems were detected in this study. 
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The gastrointestinal sequelae were the most prevalent morbidities detected in our CDH 
survivors. 
 
Musculoskeletal outcome 
CDH survivors may suffer from musculoskeletal abnormalities until their growth has 
stopped, since there is a close relationship between the development of the lung, 
diaphragm, and the thoracic cage [19]. Chest asymmetry and pectus deformity are the 
most commonly described, followed by vertebral deformities (scoliosis and kyphosis) 
[13]. Excessive tension on the diaphragmatic repair, the thoracotomy, or the smaller 
thoracic cavity with smaller lung in the affected side are suggested as possible causes 
[13].  
 
In conclusion, CDH survivors present ongoing morbidities during infancy and 
childhood. This morbidity is more prevalent in the first years of live, and there is 
some improvement with growth. CDH survivors are a group of patients that requires 
long term periodic follow up in a multidisciplinary setting to provide adequate support 
and improve their quality of life. 
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Table 1 – Ongoing morbidity and mortality of the 39 CDH patients discharged from the 
NICU. 
 
MORBIDITY 
 
 
TOTAL 
 
PATIENTS 
UNDER 5 
YEARS 
OF AGE 
(n=30) 
 
PATIENTS 
5 YEARS 
OF AGE 
AND 
OVER  
(n=9)  
 
RESPIRATORY  
   Bronchospasm/ asthma, n (%) 
   Recurrent respiratory tract infections, n (%) 
   Chronic lung disease, n (%) 
   Long term (> 6 months) pulmonary hypertension, n (%) 
 
4 (10.2) 
3 (7.6) 
5 (12.8) 
2 (5.1) 
 
3 (10) 
3 (10) 
4 (13.3) 
2 (6.6) 
 
1 (11.1) 
0 
1 (11.1) 
0 
GASTROINTESTINAL 
   Gastro-esophageal reflux, n (%) 
   Failure to thrive, n (%) 
   Need for fundoplication, n (%) 
   Need for gastrostomy, n (%) 
 
6 (15.3) 
12 (30.7) 
2 (5.1) 
2 (5.1) 
 
6 (20) 
10 (33.3) 
2 (6.6) 
2 (6.6) 
 
0 
2 (22.2) 
0 
0 
NEUROLOGICAL  
   Neurodevelopmental delay, n (%) 
   Cerebral palsy (spastic diplegia, level II *), n (%) 
   Strabismus, n (%) 
 
5 (12.8) 
1 (4) 
1 (4) 
 
4 (13.3) 
0 
1 (3.3) 
 
1 (11.1) 
1 (11.1) 
0 
MUSCULOSKELETAL  
   Pectus excavatum, n (%) 
   Scoliosis, n (%) 
 
6 (15.3) 
4 (10.2) 
 
3 (10) 
3 (10) 
 
3 (33.3) 
1 (11.1) 
SURGICAL PROBLEMS  
   Recurrence of hernia, n (%) 
   Patch rejection, n (%) 
 
4 (10.2) 
1 (2.5) 
 
2 (6.6) 
1 (3.3) 
 
2 (22.2) 
0 
DECEASED n (%) 2 (7.6) 1 (3.3) 1 (11.1) 
 * according to the Gross Motor Function Classification System 6 
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Table 2 – Different aspects of the therapy used in our CDH survivors. 
 
Morbidity 
 
Therapy 
 
Asthma / 
Bronchospasm 
 
Reduce environemental exposures; treat co-morbidity conditions as rhinitis, 
sinusitis and gastro-esophageal reflux; pharmacotherapy is used according to 
NAEPP guidelines 13 
 
Recurrent 
respiratory 
tract infections 
 
Minimize contacts, nursery > 3 years age; Palivizumab 1st and 2nd Autumns and 
Winters, annual influenza vaccine > 6 months age, pneumococal conjugated 
polysaccharide vaccine (2, 4, 6, 15 months age), purified polysaccharide 23 
valent pneumococal vaccine (PPV23) > 2 years age 
 
Chronic lung 
disease 
 
Oxygentherapy for saturation 90-95%, bronchodilators, inhaled steroids, 
nutritional support, kynesitherapy; may need tracheotomy and respiratory 
support; we usually don’t use diuretics 
 
Failure to thrive 
 
Caloric supplementation, nocturnal parenteral nutrition, gavage or gastrostomy 
for selected cases 
 
Gastro-esophageal 
reflux 
 
Dietary measures (volumes, thickening of formulas), positioning measures 
(prone, upright, carried position), procinetic agents, antacids, histamine-2 
receptor antagonists (mild-to-moderate reflux esophagitis), proton pump 
inhibitors (severe and erosive esophagitis); surgery / fundoplication in intractable 
reflux, particularly those with refractory esophagitis or strictures, and those at 
risk for significant morbidity from chronic pulmonary disease 
 
Neurodevelopmental 
delay 
 
Assess presence of psychological risk factors (parents education, mental health, 
other problems), referral for subspecialty medical services (geneticist, 
endocrinologist, neurologist), referral for non-medical interventions and 
developmental promotion 
 
Cerebral palsy 
 
Multidisciplinary approach including physical therapists, speech pathologists, 
social workers, educators, development psychologists; parents are taught how to 
work with their child in daily activities and exercises designed to prevent the 
development of contractures; adaptative equipments (walkers, poles, standing 
frames, motorized wheelchairs, special feeding devices) surgical soft tissues 
procedures, rhizotomy procedure, assessment and treatment of lower urinary 
tract dysfunction ; drugs to treat spasticity including oral dantrolene sodium, 
benzodiazepines, baclofen, levodopa, carbamazepine, trihexyphenidyl and 
injection of botulinium toxin, may be used in selected cases. 
 
Strabismus 
 
Ophthalmic specialized correction; the causative types must be distinguished and 
treated accordingly. 
 
Pectus excavatum 
 
Based on severity of the deformity and extent of physiologic compromise: 
careful observation; use of physical therapy to address musculoskeletal 
compromise, and corrective surgery when significant physiologic compromise 
 
Scoliosis 
 
Depends on the extent of the curve and the degree of skeletal maturation. 
Treatment options include reassurance, observation, bracing, and surgery (spinal 
fusion) 
 
Recurrence of hernia 
and patch rejection 
 
Surgery, reconstruction by direct muscle closure if possible; in large defects the 
use of a reverse latissimus dorsi muscle flap 
NAEPP – National Asthma Education and Prevention Program  
 
 
